Diabetology and USV in licensing accord for oral insulin for the Indian market

UK-based Diabetology Limited and Mumbai, India-based USV Limited, which has a leadership position in the Indian oral anti-diabetic market, have entered into a licence agreement to complete the development and commercialization of Diabetology’s oral insulin for the Indian market.

Under the terms of the deal, Diabetology will receive milestone payments and royalties on sales as the product completes development, regulatory and commercialization milestones. USV will spearhead the development process in India and, once regulatory approval is gained, will be responsible for the commercialization of Diabetology’s oral insulin within the large and rapidly growing Indian diabetes market. The collaboration looks forward to offering an important new therapeutic product to the more than 60 million people with diabetes in India.

Diabetology’s oral insulin offers potential major benefits to those with diabetes as well as to their clinicians and carers, the company claims, noting that its insulin candidate benefits not only from the opportunity of administering insulin in a convenient, easy-to-swallow capsule, especially important for the young, elderly or needlephobic, but also from important potential safety and efficacy benefits due to its route of delivery mimicking the body’s natural route of insulin production.